Exploring early-stage lung cancer with different characteristics using multi-omics

Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes

This study is trying to understand the different types of early-stage lung cancer by looking at their unique characteristics to see if this can help predict outcomes and find new treatment options for patients.

Quick facts

• Study type: Observational
• Enrollment: 300 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Central South University (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Changsha, Hunan)
• Trial ID: NCT06699979 on ClinicalTrials.gov

What this trial studies

This observational study aims to investigate the multi-omics characterization of early-stage lung cancer that exhibits distinct phenotypes, including those associated with cystic airspaces and multiple primary lung cancers. The study will analyze differences in the pathogenesis of non-small cell lung cancer (NSCLC) and explore whether differential gene expressions can lead to prognostic models and therapeutic targets. Participants will be followed post-surgery to assess recurrence rates and time to recurrence, providing valuable insights into the disease's behavior.

Who should consider this trial

Good fit: Ideal candidates include patients aged 18-75 with histopathologically confirmed stage I-II NSCLC and an ECOG score of 0-1.

Not a fit: Patients with a history of previous or co-existing malignant tumors or those who have received systemic anti-tumor therapies prior to enrollment may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved prognostic models and targeted therapies for early-stage lung cancer patients.

How similar studies have performed: While this study employs a multi-omics approach, similar studies have shown promise in understanding cancer phenotypes, suggesting potential for success.

Eligibility criteria

Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer

Inclusion criteria:

1. Male or female patients:18-75 years old;
2. ECOG score:0-1;
3. Histopathologically confirmed TNM stage I-II NSCLC;
4. Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);
5. Good compliance, family members agree to cooperate to receive survival follow-up;
6. Understand and voluntarily sign the informed consent.

Exclusion criteria:

1. A history of previous or co-existing malignant tumors;
2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
3. Refusal to participate in the study.

Cohort 2: Multi-omics study of lung cancer associated with cystic airspaces

Inclusion criteria:

1. Male or female patients:18-75 years old;
2. ECOG score:0-1;
3. Histopathologically confirmed TNM stage I-II NSCLC;
4. CT findings show solitary or multiple nodules with cystic airspaces.

Exclusion criteria:

1. A history of previous or co-existing malignant tumors;
2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;
3. Refusal to participate in the study.

Where this trial is running

Changsha, Hunan

• The Second Xiangya Hospital of Central South University — Changsha, Hunan, China (Recruiting)

Study contacts

• Study coordinator: Chen Chen

Conditions Lung Cancer Associated With Cystic Airspaces; Multiple Primary Lung Cancers; Non-Small Cell Lung Cancer